Abstracts:

2002, Pediatric Academic Societies
Title: Safety and Pharmacokinetics of an Anti-Lipoteichoic Acid Humanized Mouse Chimeric Monoclonal Antibody in Healthy Adults
Study: MAB-A001, Phase I (Adult study)
2002 PAS Abstract - MAB-A001 Phase I Study

2004, Pediatric Academic Societies
Title: Phase I/II Double Blind, Placebo Controlled, Dose Escalation, Safety and Pharmacokinetics Study in Very Low Birth Weight Neonates of BSYX-A110, an Anti-Staphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections
Study: MAB-N002, Phase I/II (Neonates)
2004 PAS Abstract - MAB-N002 Phase I-II Study

2006, Pediatric Academic Societies
Title: Phase II Randomized, Double Blind, Placebo-Controlled, Safety, Pharmacokinetics (PK), and Clinical Activity Study in Very Low Birth Weight (VLBW) Neonates of Pagibaximab, a Monoclonal Antibody for the Prevention of Staphylococcal Infection
Study: MAB-N003, Phase IIa (Neonates)
2006 PAS Abstract - MAB-N003 Phase IIa Study

Other Biosynexus Publications:

1. Weidenmaier, C., J.F. Kokai-Kun, E. Kulauzovic, T. Kohler, G. Thumm, H. Stoll, F. Götz, and A. Peschel. 2008. Differential roles of sortase-anchored surface proteins and wall teichoic acid in Staphylococcus aureus nasal colonization. International Journal of Medical Microbiology. E-publication ahead of press.
   
   
2. Stapleton, M.R., M.J. Horsburgh, E. Hayhurst, L. Wright, I-M. Jonsson, A. Tarkowski, J.F. Kokai-Kun, J.J. Mond, and S.J. Foster. 2007. Characterization of IsaA and SceD, two putative lytic transglycosylases of Staphylococcus aureus. Journal of Bacteriology. 189:7316-7325.
    
3. Kokai-Kun, J.F., T. Chanturiya, and J.J. Mond. 2007.Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. Journal of Antimicrobial Chemotherapy. 60:1051-1059.
    
4. Braun, L.E., D.E. Sutter, M.C. Eichelberger, L. Pletneva, J.F. Kokai-Kun, J.C. Blanco, G.A. Prince, M.G. Ottolini. 2007. Co-infection of the cotton rat (Sigmodom hispidus) with Staphylococcus aureus and influenza A virus results in synergistic diseases. Microbial Pathogenesis. 43:208-216.
    
5. Clarke, S.R., R. Mohamed, L. Bian, A.F. Routh, J.F. Kokai-Kun, J.J. Mond, A. Tarkowski, and S.J. Foster. 2007. The Staphylococcus aureus surface protein IsdA mediates resistance to innate defenses of human skin. Cell-Host & Microbe. 1:199-212.
    
6. Kusuma, C., A. Jadanova, T. Chanturiya, and J.F. Kokai-Kun. 2007.Lysostaphin resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrobial Agents and Chemotherapy. 51:475-482.
    
7. Cosgrove, K., G. Coutts, I.-M. Jonsson, A. Tarkowski, J.F. Kokai-Kun, J.J. Mond, and S.J. Foster. 2007. Catalase (KatA) and alkyl hydroperoxidase reductase (AhpC) have compensatory roles in peroxide stress resistance and are required for survival persistence and nasal colonization in Staphylococcus aureus. Journal of Bacteriology. 189:1025-1035.
    
8. Clarke, S.R., K.J. Brummell, M.J. Hosburgh, P.W. McDowell, S.A. Syed-Mohammed, M.R. Stapleton, J. Acevedo, R.C. Read, N.P.J. Day, S.J. Peacock, J.J. Mond, J.F. Kokai-Kun, and S.J. Foster. 2006.Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccination for protection against nasal carriage. The Journal of Infectious Diseases. 193:1098-1108. 
   
   
9. Kusuma, C.M. and J.F. Kokai-Kun. 2005.Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 49:3256-3263.
    
10. Walsh, S., J.F. Kokai-Kun, A. Shah, and J. Mond . 2004. Extended nasal residence time of lysostaphin and an anti-staphylococcal monoclonal antibody by delivery in semi-solid or polymeric carriers. Pharmaceutical Research. 21:1763-1768.
     
11. Weidenmaier, C., J.F. Kokai-Kun, S.A. Kristian, T. Chanturiya, H. Kalbacher, M. Gross, G. Nicholson, B. Neumeister, J.J. Mond, and A. Peschel. 2004. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nature Medicine 10:243-245.
     
12. Shah, A., J.J. Mond and S. Walsh. 2004. Lysostaphin-coated catheters eradicate Staphylococcus aureus challenge and block surface colonization. Antimicrobial Agents and Chemotherapy 48:2704-2707.
     
13. Wu, J.A., C. Kusuma, J.J. Mond, and J.F. Kokai-Kun. 2003.Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrobial Agents and Chemotherapy 47:3407-3414.
     
14. von Eiff, C., J.F. Kokai-Kun, K. Becker, and G. Peters. 2003. In vitro activity of recombinant homogenous mature lysostaphin against Staphylococcus aureus isolated from anterior nares and blood. Antimicrobial Agents and Chemotherapy 47:3613-3615.
    
15. Kokai-Kun, J.F., S.M. Walsh, T.A. Chanturiya and J.J. Mond. 2003. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrobial Agents and Chemotherapy 47:1589-1597.
     
16. Walsh, S., A. Shah and J.J. Mond. 2003. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrobial Agents and Chemotherapy 47:554-558.

Book Chapters and Reviews:

1. Kokai-Kun, J.F. 2008. “The Cotton Rat as a Model for Staphylococcus aureus Nasal Colonization in Humans.” In F. Deleo and M. Otto (eds.), Bacterial Pathogenesis: Methods and Protocols. Humana Press, Inc. New Jersey.
   
   
2. Mond, J.J. and J.F. Kokai-Kun . 2007. “The Multifunctional Role of Antibodies in the Protective Response to Bacterial T Cell-Independent Antigens.” In T. Manser (ed.) Specialization and Complementation of Humoral Immune Responses to Infection. Current Topics in Microbiology and Immunology. Springer. Berlin. Vol. 319:17-40.
   
   
3. Kokai-Kun, J.F. and J.J. Mond. 2004. “Antibody therapy for treatment or prevention of infectious diseases.” Drug Discovery Today: Therapeutic Strategies. Vol. 1, No. 4: 475-481.